Reelife12.5 mg+5 mg

Reelife is a fixed-dose combination of a tricyclic antidepressant (amitriptyline) and a benzodiazepine anxiolytic (chlordiazepoxide), indicated for:

• Established/approved use: Treatment of depression associated with moderate-to-severe anxiety, in patients who require concurrent management of both depressive and anxiety symptoms.

Reelife is not first-line therapy for anxiety or depression alone; it is reserved for patients whose depression is accompanied by significant anxiety symptoms that require dual treatment. It is not indicated for mild anxiety or as monotherapy for anxiety disorders without accompanying depression, and it is not indicated for use in children or adolescents for depression, as safety and efficacy have not been established in this population.

Each tablet of Amitriptyline + Chlordiazepoxide contains a fixed-dose combination of amitriptyline hydrochloride (a tricyclic antidepressant) and chlordiazepoxide (a benzodiazepine), commonly available in strengths such as amitriptyline 12.5 mg + chlordiazepoxide 5 mg, and amitriptyline 25 mg + chlordiazepoxide 10 mg. Exact strengths and ratios may vary by manufacturer/formulation.

Reelife combines two active substances with complementary actions: amitriptyline, a tricyclic antidepressant that increases the availability of serotonin and norepinephrine in the brain, and chlordiazepoxide, a benzodiazepine that enhances the inhibitory effects of the neurotransmitter GABA to relieve anxiety and promote calmness. This combination is used when a patient's depression is significantly complicated by anxiety, allowing both the mood and anxiety components of the illness to be addressed together. Reelife should only be used under close medical supervision because of the cardiac and central nervous system risks associated with both components.

Reelife belongs to the therapeutic class of Tricyclic Antidepressant and Benzodiazepine Combinations, used in the management of depression with associated anxiety.

Amitriptyline + Chlordiazepoxide combines two agents with distinct mechanisms of action.

• Amitriptyline is a tricyclic antidepressant (TCA) that inhibits the presynaptic reuptake of serotonin and norepinephrine, increasing their concentration in the synaptic cleft. It also has significant anticholinergic, antihistaminic, and alpha-adrenergic blocking properties, which account for many of its side effects.
• Chlordiazepoxide is a benzodiazepine that binds to the GABA-A receptor complex, enhancing the inhibitory effect of gamma-aminobutyric acid (GABA), producing anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects.

Together, Amitriptyline + Chlordiazepoxide provides both antidepressant and anxiolytic activity, though onset of the antidepressant effect typically takes 1-3 weeks, while the anxiolytic effect of chlordiazepoxide is more immediate.

Reelife tablets should be swallowed whole with a glass of water, with or without food. If a larger portion of the daily dose is prescribed at bedtime, it should be taken shortly before sleep to reduce daytime sedation. Doses should not be doubled to make up for a missed dose. Do not stop taking Reelife suddenly after prolonged use; the dose should be gradually reduced under medical supervision to avoid withdrawal and discontinuation symptoms.

Reelife has several clinically significant drug interactions:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use, or use within 14 days of an MAOI, can cause hyperpyrexia, severe convulsions, hypertensive crisis, or death; concurrent use is contraindicated (see Contraindications).
• CNS depressants (alcohol, opioids, sedative-hypnotics, other benzodiazepines): Additive sedation with risk of profound respiratory depression, coma, and death; avoid combined use where possible.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine): May increase amitriptyline plasma concentrations, raising the risk of cardiotoxicity and anticholinergic side effects.
• Other anticholinergic drugs: Additive anticholinergic effects (e.g., severe constipation, urinary retention, paralytic ileus, hyperthermia).
• Drugs that prolong the QT interval (certain antiarrhythmics, antipsychotics, some antibiotics): Additive risk of cardiac arrhythmia.
• Sympathomimetics (e.g., epinephrine): Amitriptyline may potentiate cardiovascular effects, increasing the risk of arrhythmia and hypertension.

Side effects of Reelife arise from both its antidepressant and benzodiazepine components.

Common

• Drowsiness and dizziness
• Dry mouth, blurred vision, constipation
• Weight gain
• Orthostatic hypotension and mild tachycardia
• Impaired coordination and concentration

Serious (seek medical attention)

• Cardiac arrhythmias, palpitations, or fainting
• Severe confusion, hallucinations, or worsening mood/suicidal thoughts
• Urinary retention or paralytic ileus
• Seizures
• Signs of dependence or withdrawal on stopping treatment
• Rarely: jaundice, blood disorders, or severe allergic reactions

Reelife should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician must be consulted before use. Use of benzodiazepines late in pregnancy has been associated with neonatal sedation and, with prolonged use, neonatal withdrawal symptoms (irritability, feeding difficulty, "floppy infant" syndrome). Amitriptyline has not been shown to be free of risk to the fetus. Reelife should generally be avoided during breastfeeding, as both components pass into breast milk and may cause sedation or feeding problems in the nursing infant; if use is considered essential, it should be under close medical supervision with monitoring of the infant.

Reelife requires careful use and monitoring due to the following:

• Cardiac risk: May cause QT prolongation and conduction abnormalities; use with caution in patients with cardiovascular disease, arrhythmia, or a family history of sudden cardiac death.
• Suicidality: Antidepressants may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor closely, especially early in treatment.
• Dependence and withdrawal: Chlordiazepoxide can cause physical and psychological dependence; do not stop Reelife abruptly after prolonged use, as this may precipitate withdrawal (anxiety, insomnia, tremor, seizures).
• Sedation and psychomotor impairment: May impair the mental and/or physical abilities required for driving or operating machinery; avoid alcohol.
• Elderly patients: Increased sensitivity to anticholinergic and sedative effects with a higher risk of confusion and falls; use lower doses.
• Seizure disorders: May lower the seizure threshold; use with caution in patients with a history of seizures.
• Angle-closure glaucoma and urinary retention risk: Anticholinergic effects may worsen these conditions.
• Hyperthyroidism/thyroid therapy: May increase the risk of cardiac arrhythmia.

Overdose with Reelife is potentially life-threatening, primarily due to the cardiotoxic effects of the tricyclic antidepressant component, and may present with cardiac arrhythmias, severe hypotension, seizures, and coma, in addition to profound sedation and respiratory depression from the benzodiazepine component. Overdose of Reelife is a medical emergency; seek immediate medical attention or contact emergency services/poison control immediately. Do not attempt to treat an overdose at home, and do not induce vomiting unless instructed by a healthcare professional or poison control.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Use lower initial doses of Reelife due to increased sensitivity to sedative, anticholinergic, and cardiac effects, and a higher risk of falls and confusion.

Renal impairment: No well-established dose adjustment; use cautiously with monitoring.

Hepatic impairment: Use with caution and a reduced dose in mild-to-moderate impairment; contraindicated in severe hepatic impairment.

Cardiac disease: Use with caution given the risk of conduction abnormalities and arrhythmia; a baseline ECG may be considered in at-risk patients.

Pregnant/breastfeeding women: See Pregnancy and Lactation.

The duration of treatment with Reelife is individualized by the treating physician based on clinical response, and typically continues for several months once depressive and anxiety symptoms have improved, to reduce the risk of relapse. Because of the dependence potential of the chlordiazepoxide component, long-term or indefinite use is generally avoided, and treatment should be reviewed periodically. Discontinuation should always be gradual, with dose tapering over a period determined by the physician, rather than abrupt cessation.

Amitriptyline + Chlordiazepoxide is a combination of two distinct drug classes: a tricyclic antidepressant (amitriptyline) and a benzodiazepine anxiolytic/sedative (chlordiazepoxide).

Amitriptyline + Chlordiazepoxide acts through two complementary mechanisms: amitriptyline blocks the reuptake of serotonin and norepinephrine at nerve terminals, increasing their levels in the brain to relieve depressive symptoms, while chlordiazepoxide enhances GABA-mediated inhibitory neurotransmission at the GABA-A receptor to produce anxiolytic and calming effects.

D

Safety and efficacy of Reelife have not been established in children and adolescents under 18 years of age. Reelife is not recommended for use in this population. Antidepressant use in children, adolescents, and young adults has been associated with an increased risk of suicidal thinking and behavior; if used in this age group under specialist guidance for another approved indication, close monitoring is required.